Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Fulvestrant'

Fulvestrant published presentations and documents on DocSlides.

Fulvestrant 500 mg versus
Fulvestrant 500 mg versus
by elena
anastrozole. as first-line treatment for advanced...
BELLE-3: A Phase III Study of
BELLE-3: A Phase III Study of
by faustina-dinatale
Buparlisib. and . Fulvestrant. in Postmenopausa...
Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
by olivia-moreira
Jointly provided by ...
Module 8: ER-Positive Metastatic
Module 8: ER-Positive Metastatic
by anastasia
Breast Cancer . Elizabeth O’Reilly, MSN, MPH, AN...
Her-2 negative MBC
Her-2 negative MBC
by conchita-marotz
10/25/2016. Objectives. General principles. Endoc...
Hormone Receptor-Positive Advanced Breast Cancer:
Hormone Receptor-Positive Advanced Breast Cancer:
by min-jolicoeur
HR Advanced Breast Cancer:. Introduction. Case S...
The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer
The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer
by min-jolicoeur
HR Advanced Breast Cancer. Introduction. Restagi...
Targeting endocrine-resistance pathways in breast cancer
Targeting endocrine-resistance pathways in breast cancer
by alexa-scheidler
Targeting endocrine-resistance pathways in breas...
Hormone Receptor Positive Metastatic Breast Cancer
Hormone Receptor Positive Metastatic Breast Cancer
by pamella-moone
. 5/9/2017. The Lancet July 11, 1895. ON THE TRE...
Endocrine Treatment of Metastatic Breast Cancer: New Advances; Patient Education Implications
Endocrine Treatment of Metastatic Breast Cancer: New Advances; Patient Education Implications
by calandra-battersby
An Interactive Oncology Grand Rounds Series. Joyc...
PrECOG 0102: A Randomized, Double-Blind Phase II Trial of Fulvestrant plus Everolimus or Placebo
PrECOG 0102: A Randomized, Double-Blind Phase II Trial of Fulvestrant plus Everolimus or Placebo
by tawny-fly
Post-Menopausal Women with Hormone-Receptor Posit...
Endocrine resistance: molecular pathways and rational development of targeted therapies
Endocrine resistance: molecular pathways and rational development of targeted therapies
by spottletoefacebook
Grazia Arpino. Università di Napoli Federico II. ...
CDK4-6 INHIBITORS IN Breast Cancer: Optimal Treatment Sequencing
CDK4-6 INHIBITORS IN Breast Cancer: Optimal Treatment Sequencing
by leah
Mansoor A Khan, BS, MS, BCOP. Oncology/Hematology/...
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor
by byrne
Overall survival and updated progression-free surv...